In this study we assessed the ability of Middle East respiratory syndrome coronavirus (MERS-
CoV) to replicate and induce innate immunity in human monocyte-derived macrophages …

Middle East respiratory syndrome coronavirus (MERS-CoV) infection caused severe
pneumonia and multiorgan dysfunction and had a higher crude fatality rate (around 50% vs …

Abstract The Middle East respiratory syndrome coronavirus (MERS-CoV) closely resembled
severe acute respiratory syndrome coronavirus (SARS-CoV) in disease manifestation as …

Abstract Middle-East Respiratory Syndrome coronavirus (MERS-CoV) was identified to
cause severe respiratory infection in humans since 2012. The continuing MERS epidemic …

ABSTRACT The Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in
2012 as the causative agent of a severe respiratory disease with a fatality rate of …

The high mortality associated with the novel Middle East respiratory syndrome coronavirus
(MERS-CoV) has raised questions about the possible role of a cytokine storm in its …

Middle East respiratory syndrome coronavirus (MERS‐CoV) first emerged in late 2012.
Since its emergence, a total of 2279 patients from 27 countries have been infected across …

Middle East respiratory syndrome coronavirus (MERS-CoV) is an important emerging
pathogen that was first described in 2012. While the cell surface receptor for MERS-CoV has …

Background An understanding of immune responses against the Middle East respiratory
syndrome (MERS) is important for the development of treatments and preventive measures …

Middle East respiratory syndrome (MERS) is associated with a mortality rate of> 35%. We
previously showed that MERS coronavirus (MERS-CoV) could infect human macrophages …